Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Annals of Oncology

• Publication date

  2003-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/ANNONC/MDG112PMID 12598351
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Platinum compounds in the treatment of advanced breast cancer.

  2001cited by this paper
• Treatment of recurrent and metastatic endometrial carcinoma with cisplatin and doxorubicin.

  1994cited by this paper
• Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin.

  1993cited by this paper
• Circadian‐Timed Combination Doxorubicin‐Cisplatin Chemotherapy for Advanced Endometrial Carcinoma: A Phase II Study of the Gynecologic Oncology Group

  1990cited by this paper
• Phase II trial of clsplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: A gynecologic oncology group study

  1989cited by this paper
• Phase II trial of cisplatin as first‐line chemotherapy in patients with advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study

  1989cited by this paper
• Hexamethylmelamine as first‐line chemotherapy in the treatment of advanced or recurrent carcinoma of the endometrium: A phase II trial of the Gynecologic Oncology Group

  1989cited by this paper
• Cytotoxic chemotherapy for patients with endometrial carcinoma.

  1986influential reference
• Cytotoxic chemotherapy for patients with endometrial carcinoma.

  1986cited by this paper
• Treatment of advanced endometrial carcinoma with doxorubicin and cisplatin: effects on both untreated and previously treated patients.

  1985cited by this paper
• Adriamycin and cis-diamminedichloroplatinum in the treatment of metastatic endometrial adenocarcinoma.

  1984cited by this paper
• Treatment of recurrent endometrial adenocarcinoma with a combination of doxorubicin and cisplatin.

  1984cited by this paper
• Chemotherapeutic treatment of endometrial carcinoma.

  1982cited by this paper
• Combination chemotherapy for advanced endometrial cancer. An evaluation of three regimens

  1982cited by this paper
• Carcinoma of the endometrium

  1981cited by this paper
• Improved chemotherapy for ovarian cancer with cis‐diamminedichloroplatinum and adriamycin

  1981cited by this paper
• Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial.

  1975cited by this paper
• Planning the size and duration of a clinical trial studying the time to some critical event.

  1974influential reference
• Nonhormonal chemotherapy of endometrial adenocarcinoma: A review

  1974cited by this paper
• Endometrial cancer: approach to development of effective chemotherapy.

  1974cited by this paper
• Evaluation of survival data and two new rank order statistics arising in its consideration.

  1966cited by this paper
• Carcinoma of the endometrium.

  1962cited by this paper
• Progestational agents in the treatment of carcinoma of the endometrium.

  1961cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• Regression Models and Life-Tables

  year unknowncited by this paper

• Lenvatinib and pembrolizumab versus platinum doublet chemotherapy as second-line therapy for advanced or recurrent endometrial cancer

  2024cites this paper
• Management of endometrial cancer in Latin America: raising the standard of care and optimizing outcomes

  2024cites this paper
• First-line treatments for advanced or recurrent endometrial cancer: systematic literature review of clinical evidence.

  2024cites this paper
• Co-delivery of carboplatin and doxorubicin using ZIF-8 coated chitosan-poly(N-isopropyl acrylamide) nanoparticles through a dual pH/thermo responsive strategy to breast cancer cells.

  2024cites this paper
• Empowering High Throughput Screening of 3D Models: Automated Dispensing of Cervical and Endometrial Cancer Cells

  2024cites this paper
• Association Between Intermediate End Points, Progression-Free Survival, and Overall Survival in First-Line Advanced or Recurrent Endometrial Cancer.

  2023cites this paper
• Pivotal Science From the 2022 International Gynecologic Cancer Society Meeting.

  2023cites this paper
• Radiotherapy and Chemotherapy Features in the Treatment for Locoregional Recurrence of Endometrial Cancer: A Systematic Review

  2023cites this paper
• Efficient sequence of therapy for advanced and metastatic endometrial cancer

  2022cites this paper
• Adjuvant and first line chemotherapy use for endometrial cancer

  2022cites this paper
• Effect of primary prophylaxis with pegfilgrastim in endometrial cancer patients treated with doxorubicin and cisplatin.

  2022cites this paper
• Malignant diseases of the uterus

  2022cites this paper
• The Role of HECT-Type E3 Ligase in the Development of Cardiac Disease

  2021cites this paper
• British Gynaecological Cancer Society (BGCS) uterine cancer guidelines: Recommendations for practice.

  2021cites this paper
• Adjuvant and post-surgical treatment in endometrial cancer.

  2021cites this paper
• A Microfluidic Multisize Spheroid Array for Multiparametric Screening of Anticancer Drugs and Blood–Brain Barrier Transport Properties

  2021cites this paper
• Recurrent Endometrial Cancer: Local and Systemic Treatment Options

  2021cites this paper
• Nanoparticle-based drug delivery systems with platinum drugs for overcoming cancer drug resistance.

  2021cites this paper
• Pharmacological Treatment of Advanced, Persistent or Metastatic Endometrial Cancer: State of the Art and Perspectives of Clinical Research for the Special Issue “Diagnosis and Management of Endometrial Cancer”

  2021cites this paper
• A phase II, open-labeled, single-arm study of dose-dense paclitaxel plus carboplatin in advanced or recurrent uterine endometrial cancer treatment: a KCOG-G1303, DOENCA trial

  2021cites this paper
• Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) vs CRS alone for treatment of endometrial cancer with peritoneal metastases: a multi-institutional study from PSOGI and BIG RENAPE groups

  2021cites this paper
• Adjuvant treatment of endometrial cancer today.

  2020cites this paper
• Interactions of Cisplatin and Daunorubicin at the Chromatin Level

  2020cites this paper
• Avanços na quimioterapia do câncer ginecológico: uma revisão

  2020cites this paper
• Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).

  2020cites this paper
• Recurrent Endometrial Cancer

  2020cites this paper
• Recent Advances in Endometrial Cancer

  2020cites this paper
• Review: Clinical Trials Outcome for Chemotherapy in Endometrial Cancer

  2020cites this paper
• Nanomaterial‐mediated platinum drug‐based combinatorial cancer therapy

  2020cites this paper
• Current recommendations and recent progress in endometrial cancer

  2019cites this paper
• Endometrial Cancer

  2019cites this paper
• Systemic therapy for the treatment of endometrial cancer

  2019cites this paper
• Uterine Cancer: Adjuvant Therapy and Management of Metastatic Disease.

  2019cites this paper
• Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.

  2019cites this paper
• Platinum rechallenge in second-line treatment for endometrial carcinoma

  2019cites this paper
• A phase I/II study of GLIF combination chemotherapy for taxane/platinum-refractory/resistant endometrial cancer (GOGO-EM2)

  2018cites this paper
• Combined therapies with nanostructured carbon materials: there is room still available at the bottom.

  2018cites this paper
• Adjuvant therapy in patients with clear cell endometrial carcinoma: An analysis of the National Cancer Database.

  2018cites this paper
• Management Strategies for Recurrent Endometrial Cancer

  2018cites this paper
• 18 Prevention and Therapeutic Strategies in Endometrial Cancer

  2018cites this paper
• Home Testing of Blood Counts in Patients with Cancer

  2018cites this paper
• Cancer of the corpus uteri

  2018cites this paper
• Endometrial cancer: Molecular markers and management of advanced stage disease.

  2018cites this paper
• Synergistic Activation of Doxorubicin against Cancer : A Review

  2018cites this paper
• Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer

  2017cites this paper
• Traitement médical du cancer de l’endomètre avancé

  2017cites this paper
• Synergistic Cisplatin/Doxorubicin Combination Chemotherapy for Multidrug-Resistant Cancer via Polymeric Nanogels Targeting Delivery.

  2017cites this paper
• Cisplatin-crosslinked glutathione-sensitive micelles loaded with doxorubicin for combination and targeted therapy of tumors.

  2017cites this paper
• Pituitary adenylate cyclase-activating polypeptide (PACAP) in zebrafish models of nephrotic syndrome

  2017cites this paper
• Expression of neurotensin receptor 1 in endometrial adenocarcinoma is correlated with histological grade and clinical outcome

  2017cites this paper
• [Systemic therapy for advanced endometrial cancer].

  2017cites this paper
• Cáncer de cérvix. Cáncer de endometrio

  2017cites this paper
• BGCS uterine cancer guidelines: Recommendations for practice.

  2017cites this paper
• Formation of starch in plant cells

  2016cites this paper
• An update on the current pharmacotherapy for endometrial cancer

  2016cites this paper
• Biweekly administration of docetaxel and carboplatin for advanced or recurrent endometrial and ovarian carcinomas.

  2016cites this paper
• Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings.

  2016cites this paper
• Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement

  2016cites this paper
• Update on chemotherapy in gynaecological cancers

  2016cites this paper
• Safety and Anti-tumor Effects of Docetaxel Plus Cisplatin in Intermediate- and High-risk Endometrial Cancer.

  2016cites this paper
• Endometrial cancer: redefining the molecular-targeted approach

  2015cites this paper
• Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor

  2015cites this paper
• The effect of molecular target drug, erlotinib, against endometrial cancer express ing high levels of epidermal growth factor receptor

  2015cites this paper
• ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up.

  2015cites this paper
• ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up.

  2015cites this paper
• Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer.

  2015cites this paper
• ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer

  2015cites this paper
• Cancer of the corpus uteri

  2015cites this paper
• Carboplatin and Nonpegylated Liposomal Doxorubicin in Primary Advanced or Recurrent Endometrial Cancer: A Phase 2 Trial Conducted by AGO Austria

  2015cites this paper
• Chemotherapy and/or Targeted Therapies for Advanced Endometrial Cancer: Time to Rethink?

  2014cites this paper
• Taxanes: their impact on gynecologic malignancy

  2014cites this paper
• A phase 2 trial of radiation therapy with concurrent paclitaxel chemotherapy after surgery in patients with high-risk endometrial cancer: a Korean Gynecologic Oncologic Group study.

  2014cites this paper
• What Is the Role of Adjuvant Radiotherapy and Chemotherapy in Endometrial Cancer

  2014cites this paper
• Anthracycline‐based chemotherapy in metastatic endometrial carcinoma: An update

  2014cites this paper
• Endometrial cancer: a review and current management strategies: part II.

  2014cites this paper
• Adjuvant chemotherapy for advanced endometrial cancer.

  2014cites this paper
• Controversies in the Adjuvant Therapy of Endometrial Cancer

  2014cites this paper
• Uterine Clear Cell Carcinoma

  2014cites this paper
• Effect of mTOR Inhibitors in Nude Mice with Endometrial Carcinoma and Variable PTEN Expression Status

  2014cites this paper
• Ratiometric delivery of cisplatin and doxorubicin using tumour-targeting carbon-nanotubes entrapping platinum(IV) prodrugs

  2014cites this paper
• Oligonucleotides--assembled Au nanorod-assisted cancer photothermal ablation and combination chemotherapy with targeted dual-drug delivery of Doxorubicin and Cisplatin prodrug.

  2014cites this paper
• Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer.

  2014cites this paper
• Endometrial cancer: molecular and therapeutic aspects.

  2013cites this paper
• Current status of molecular-targeted drugs for endometrial cancer (Review)

  2013cites this paper
• Cáncer de cérvix y endometrio

  2013cites this paper
• Adjuvant sequential chemoradiation therapy in high-risk endometrial cancer: results of a prospective, multicenter phase-II study of the NOGGO (North-Eastern German Society of Gynaecological Oncology)

  2013cites this paper
• Endometrial carcinoma: treatment.

  2012cites this paper
• 32-Neoplastic Diseases of the Uterus

  2012cites this paper
• Endometrial carcinoma : treatment

  2012cites this paper
• [Systemic therapy for advanced endometrial cancer].

  2012cites this paper
• The antitumor agent doxorubicin binds to Fanconi anemia group F protein.

  2012cites this paper
• Cancer of the corpus uteri

  2012cites this paper
• 10 Adjuvant Chemotherapy for Endometrial Cancer

  2012cites this paper
• Co-delivery of daunomycin and oxaliplatin by biodegradable polymers for safer and more efficacious combination therapy.

  2012cites this paper
• Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma.

  2012cites this paper
• Contemporary management of endometrial cancer.

  2012cites this paper
• EORTC Gynecological Cancer Group on the frontline of practice-changing clinical trials

  2012cites this paper
• Cancer Endometrium: An Update

  2012cites this paper
• Adjuvant Chemotherapy for Endometrial Cancer

  2012cites this paper
• Traitement systémique du cancer de l’endomètre avancé

  2012cites this paper